AstraZeneca is investing ₹166 crore to expand its Bengaluru hub, creating 400 new jobs and boosting its Indian workforce to 4,000. The upgraded center will focus heavily on AI‑supercharged healthcare — mixing digital health, centralized data analytics, clinical research, and compliance functions to fast‑track the development of 20 new medicines by 2030. This move underscores Bangalore’s emergence as a biotech and R&D powerhouse in AstraZeneca’s global strategy.
By bringing AI into the heart of drug discovery and trial operations, AstraZeneca aims to shorten development cycles and enhance trial outcomes. Karnataka’s health minister echoed the ambition, bolstering the state’s vision as a biotechnology hub. For Indian tech professionals and researchers, this signals major growth opportunities at the intersection of AI and healthcare. This is more than just an investment—it’s a statement about the future of smart medicine in India.
